IMMUNO-ONCOLOGY INSIGHTS

Novel target and pathways: driving new approaches to tackling the TME and resistance to I-O therapeutics – April 2022
Kick-starting tumor specific T cell priming & targeting the tumor microenvironment using CD40 targeting bispecific antibodies
Kick-starting tumor specific T cell priming & targeting the tumor microenvironment using CD40 targeting bispecific antibodies
K Hagerbrand,
P Ellmark
The end of an era of cancer drug discovery: life without new drug targets
The end of an era of cancer drug discovery: life without new drug targets
A Mardiros,
A Kamb
Driving disruption in the solid tumor space: is it time to shift paradigms and develop novel immuno-oncology strategies?
Driving disruption in the solid tumor space: is it time to shift paradigms and develop novel immuno-oncology strategies?
E Patz
Forging new paths in immuno-oncology
Forging new paths in immuno-oncology
R McGuigan,
M Tuna
Promise & challenges in discovering cellular immunotherapies &T cell engagers for solid tumor indications
Promise & challenges in discovering cellular immunotherapies &T cell engagers for solid tumor indications
P Sivakumar
Quantifying the tumor microenvironment: what is the next step to advance cancer immunotherapy?
Quantifying the tumor microenvironment: what is the next step to advance cancer immunotherapy?
N Wang
View all

Optimizing clinical development strategy for the rapidly evolving I-O field

1 March 2022

Dissecting investor and market access trends and drivers for I-O R&D insights

1 February 2022

Anticipating immuno-oncology modality/platform development trends for 2022

26 January 2022

Bioprocessing/CMC trends, tools and techniques

1 November 2021

Leveraging cutting edge tools to convert I-O data into knowledge

1 September 2021

Enhancing preclinical predictivity

1 July 2021
View all

  • Life on a chip - vascularized micro-tumor chips for mimicking clinical...
    C Hughes
    Chris Hughes
    Chris Hughes
    CSO at Aracari Biosciences
    8 Jun 2022
    20
    Days
    23
    Hrs
    36
    Min
    Register

  • Overcoming current challenges in immunotherapy drug development with...
    S F. Boj
    Sylvia F. Boj
    Sylvia F. Boj
    Chief Scientific Officer at Hubrecht Institute
    15 Jun 2022
    27
    Days
    23
    Hrs
    36
    Min
    Register

  • Thinking translational: Things to consider in CAR T cell research workflows
    S Rösch, PhD
    Saskia Rösch, PhD
    Saskia Rösch, PhD
    Global Product Manager at Miltenyi Biotec
    22 Jun 2022
    34
    Days
    23
    Hrs
    36
    Min
    Register

  • Accelerating cell therapy discovery & development with non-viral gene...
    D Hermanson
    X Patrinostro
    David Hermanson
    David Hermanson
    Senior Manager of R&D Applications, Cell and Gene Therapy at Bio-techne
    Xiaobai Patrinostro
    Xiaobai Patrinostro
    Manager of Genome Engineering Services, Cell and Gene Therapy at Bio-techne
    16 Jun 2022
    28
    Days
    7
    Hrs
    36
    Min
    Register

  • Monitoring of circulating CAR T cells
    A Graband,
    D Hünecke,
    D Bremm
    Annika Graband
    Annika Graband
    Product Manager, Cell Analysis Reagents at Miltenyi Biotec
    Dr. Sabine Hünecke
    Dr. Sabine Hünecke
    Head of Laboratory, Stem Cell Transplantation and Immunotherapy at University Hospital Frankfurt
    Dr. Melanie Bremm
    Dr. Melanie Bremm
    Deputy Head of Laboratory, Stem Cell Transplantation and Immunotherapy at University Hospital Frankfurt
    31 May 2022
    12
    Days
    23
    Hrs
    36
    Min
    Register
    • View all

  • Enabling clinical grade manufacturing of gene-engineered NK cells
    N Möker,
    E Ullrich,
    R Romee et al.
    Nina Möker
    Nina Möker
    R&D Reagents Manager, Allogeneic Cell Therapy, Miltenyi Biotec
    Prof. Dr. Evelyn Ullrich
    Prof. Dr. Evelyn Ullrich
    Arbeitsgruppe Zelluläre Immunologie, Universitätsklinikum, Frankfurt am Main (kgu.de)
    Rizwan Romee, MD
    Rizwan Romee, MD
    Associate Professor of Medicine, Harvard Medical School, Dana Farber Cancer Institute
    Volker Huppert
    Volker Huppert
    Chief Development Officer Glycostem Therapeutics
    30 November 2021
    Watch now

  • Advancing engineered cell and gene therapy with precision gene editing
    D Maddalo
    Danilo Maddalo
    Danilo Maddalo
    Group Leader, Translational Oncology, Genentech
    11 November 2021
    Watch now

  • Gain deeper insights into the mechanisms of immune cell killing of tumor cells:...
    C Souders,
    T Dale,
    N Bevan et al.
    Dr Colby Souders
    Dr Colby Souders
    Chief Scientific Officer, Abveris
    Tim Dale, PhD
    Tim Dale, PhD
    Head of BioAnalytics Applications, Sartorius
    Nicola Bevan
    Nicola Bevan
    Manager of Cell Imaging Applications, Sartorius
    Jeffrey Skolnik, M.D.
    Jeffrey Skolnik, M.D.
    Senior Vice President, Clinical Development, Inovio
    6 October 2021
    Watch now

  • The therapeutic gene editing solution – cell therapy for solid tumors
    B Sasu,
    P Sivakumar,
    J Trager et al.
    Barbra Sasu, PhD
    Barbra Sasu, PhD
    Chief Scientific Officer, Allogene Therapeutics
    Pallavur Sivakumar, PhD
    Pallavur Sivakumar, PhD
    Scientific Vice President and Head of Discovery, Immuno-Oncology and Cell Therapy Thematic Research Center, Bristol Myers Squibb
    James Trager, PhD
    James Trager, PhD
    Chief Scientific Officer, Nkarta Therapeutics
    Jennifer Harbottle, PhD
    Jennifer Harbottle, PhD
    Senior Scientist, R&D, Cell and Gene Therapy, Horizon Discovery
    30 September 2021
    Watch now

  • Get your non-viral T cell engineering process ready for clinical manufacturing
    M Rietenbach,
    S Wild,
    K Patel
    Melanie Rietenbach
    Melanie Rietenbach
    Global Product Manager Miltenyi Biotec
    Stefan Wild
    Stefan Wild
    Senior Manager, Research and Development, Miltenyi Biotec
    Kunal Patel
    Kunal Patel
    Process Engineering Manager, Miltenyi Biotec
    21 September 2021
    Watch now

  • Cell-based therapies for cancer treatment: leveraging advanced flow cytometry...
    N Ph.D.,
    R Fan,
    T Laskowski, Ph.D.
    Nina Senutovitch Ph.D.
    Nina Senutovitch Ph.D.
    Senior Scientist, Product Development, Cell Imaging, Sartorius
    Professor Rong Fan
    Professor Rong Fan
    Professor of Biomedical Engineering, Yale University
    Tamara J. Laskowski, Ph.D.
    Tamara J. Laskowski, Ph.D.
    Scientific Project Director, Adoptive Cell Therapy Platform, Dept. of Stem Cell Transplantation and Cellular Therapy MD Anderson Cancer Center
    5 August 2021
    Watch now
    • View all

    Latest content

    A winning combination in the war against deadly cancers: exploring new opportunities for combining antibody–drug conjugates and cancer immunotherapies

    A winning combination in the war against deadly cancers: exploring new...

    R Dixit
    Rakesh Dixit
    Rakesh Dixit
    President & CEO, Bionavigen, Gaithersburg, MD, USA and President and CSO, Regio Biosciences, Rockville, MD, USA
    25 April 2022
    Commentary
    Update on antibody–drug conjugates: where are we now, & where are we going?

    Update on antibody–drug conjugates: where are we now, & where are we...

    F Arnaldez
    Fernanda Arnaldez
    Fernanda Arnaldez
    Executive Global Product Leader – Early Development Oncology Research and Development AstraZeneca
    18 April 2022
    Viewpoint
    Kick-starting tumor specific T cell priming & targeting the tumor microenvironment using CD40 targeting bispecific antibodies

    Kick-starting tumor specific T cell priming & targeting the tumor microenvironment...

    K Hagerbrand
    P Ellmark
    Karin Hägerbrand
    Karin Hägerbrand
    Alligator Bioscience, Medicon Village, Lund, Sweden
    Peter Ellmark
    Peter Ellmark
    Alligator Bioscience, Medicon Village, Lund, Sweden Dept. Immunotechnology, Lund University, Sweden
    11 April 2022
    Expert Insight
    The end of an era of cancer drug discovery: life without new drug targets

    The end of an era of cancer drug discovery: life without new drug targets

    A Mardiros
    A Kamb
    Armen Mardiros
    Armen Mardiros
    Director, Translational Science, A2 Biotherapeutics , Inc.
    Alexander Kamb
    Alexander Kamb
    Chief Scientific Officer A2 Biotherapeutics , Inc.
    11 April 2022
    Viewpoint
    Driving disruption in the solid tumor space: is it time to shift paradigms and develop novel immuno-oncology strategies?

    Driving disruption in the solid tumor space: is it time to shift paradigms...

    E Patz
    Edward Patz
    Edward Patz
    Chief Executive Officer, Grid Therapeutics, LLC and James and Alice Chen Distinguished Professor of Radiology, Professor in Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC, USA
    8 April 2022
    Interview
    Forging new paths in immuno-oncology

    Forging new paths in immuno-oncology

    R McGuigan
    M Tuna
    Roisin McGuigan
    Roisin McGuigan
    Editor Immuno-Oncology Insights
    Mihriban Tuna
    Mihriban Tuna
    Chief Scientific Officer, Adaptate Biotherapeutics
    6 April 2022
    Foreword
    Spotlight on optimizing clinical development strategy

    Spotlight on optimizing clinical development strategy

    J O'Donnell-Tormey
    Jill O'Donnell-Tormey
    Jill O'Donnell-Tormey
    Chief Executive Officer & Director - Scientific Affairs at Cancer Research Institute
    29 March 2022
    Foreword
    Cancer immunotherapy & clinical trial design: issues & practice

    Cancer immunotherapy & clinical trial design: issues & practice

    J Dancey
    Janet E Dancey, MD, FRCPC
    Janet E Dancey, MD, FRCPC
    Canadian Cancer Trials Group Cancer Research Institute Queen’s University Kingston, Ontario, Canada
    29 March 2022
    Commentary
    Expediting drug development & targeting early-stage disease: how is clinical trial design in immuno-oncology evolving?

    Expediting drug development & targeting early-stage disease: how is...

    P Forde
    Patrick Forde
    Patrick Forde
    Director Thoracic Oncology Clinical Research Program Associate Professor of Oncology Johns Hopkins
    27 March 2022
    Interview
    View all